PDF(155 KB)
Beyond the “cold tumor” label: dimensional heterogeneity of immune resistance and dimension-matched combination strategies in gynecologic cancers
Xiufang Du¹ and Changna Fu¹
Cancer Immuno Perspectives ›› 2026, Vol. 1 ›› Issue (1) : 17-28.
PDF(155 KB)
PDF(155 KB)
Beyond the “cold tumor” label: dimensional heterogeneity of immune resistance and dimension-matched combination strategies in gynecologic cancers
Xiufang Du¹ and Changna Fu¹*
Immune checkpoint inhibitors (ICIs) have produced unequivocal but unevenly distributed clinical benefit across gynecologic malignancies. In mismatch repair-deficient (dMMR) endometrial cancer, single-agent PD-1 blockade achieves objective response rates (ORR) of approximately 42%, whereas in cervical cancer the ORR of PD-1 monotherapy is only about 12%. In ovarian cancer, multiple phase III trials combining ICIs with PARP inhibitors have reported progression-free survival (PFS) signals, yet the incremental contribution of immunotherapy remains difficult to isolate from that of the PARP inhibitor backbone, and no consistent overall survival benefit has been demonstrated. The prevailing “cold tumor” label flattens this heterogeneity into a single descriptor and offers little explanatory or therapeutic traction. This review proposes that immune resistance in gynecologic cancers operates along three distinguishable dimensions: a spatial dimension in ovarian cancer, where cancer-associated fibroblast (CAF)/extracellular matrix barriers and vascular dysfunction exclude T cells from tumor nests; a functional dimension in cervical cancer, where HPV-driven antigen persistence generates a T cell “infiltrated but dysfunctional” phenotype marked by co-expression of PD-1 with TIGIT, TIM-3, LAG-3, and NKG2A; and an identity dimension in endometrial cancer, where molecular subtype—dMMR, pMMR, p53-mutant, or NSMP—sets the baseline immune context, with pMMR tumors remaining immune-cold and p53-mutant tumors engaging tryptophan metabolic immunosuppression. We argue that the next step is dimension-matched combination logic: VEGF/VEGFR normalization for spatial exclusion, functional restoration or replacement of T cells for cervical cancer, and subtype-directed immune-context reprogramming for pMMR and p53-mutant endometrial tumors. Biomarker development should shift correspondingly from single-agent predictors toward composite, dimension-informed stratification.
gynecologic cancer
/
| 〈 |
|
〉 |